Splenic marginal zone lymphomas and lymphoplasmacytic lymphomas originate from B-cell compartments with two different antigen-exposure histories

Parrens, Marie; Gachard, Nathalie; Petit, Barbara; Marfak, Abdelghafour; Troadec, Estelle; Bouabdhalla, K.; Milpied, Noël; Merlio, Jean-Philippe; Mascarel, A. De; Laurent, Césari; Soubeyran, Isabelle; Coste, V.; Labrousse, François; Cogné, Michel; Feuillard, Jean

doi:10.1038/leu.2008.24

Cited by 6 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A majority of the SMZL cases studied carried a nonmutated bcl-6 gene [14] . The frequency of these mutations in normal spleen confirms previous findings on the hypermutation IgVH process in normal B-cell populations [27,28] . This data supported the existence of molecular heterogeneity in this entity.…”

Section: A B Csupporting

confidence: 78%

Splenectomy with chemotherapyvssurgery alone as initial treatment for splenic marginal zone lymphoma

Milošević¹

2009

WJG

View full text Add to dashboard Cite

METHODS:A total of 30 patients with typical histological and immunohistochemical SMZL patterns were examined. Splenectomy plus chemotherapy was applied in 20 patients, while splenectomy as a single treatment-option was performed in 10 patients. Prognostic factor and overall survival rate were analyzed. RESULTS:Complete remission (CR) was achieved in 20 (66.7%), partial remission (PR) in seven (23.3%), and lethal outcome due to disease progression occurred in three (10.0%) patients. Median survival of patients with a splenectomy was 93.0 mo and for patients with splenectomy plus chemotherapy it was 107.5 mo (Log rank = 0.056, P > 0.05). Time from onset of first symptoms to the beginning of the treatment (mean 9.4 mo) was influenced by spleen dimensions, as measured by computerized tomography and ultra-sound (t = 2.558, P = 0.018). Strong positivity (+++) of CD20 antigen expression in splenic tissue had a positive influence on OS (Log rank = 5.244, P < 0.05). The analysis of factors interfering with survival (by the Kaplan-Meier method) revealed that gender, general symptoms, clinical stage, and spleen infiltration type (nodular vs diffuse) had no significant (P > 0.05) effects on the OS. The expression of other antigens (immunohistochemistry) also had no effect on survival-rate, as measured by a χ 2 test (P > 0.05). CONCLUSION:Initial splenectomy combined with chemotherapy has been shown to be beneficial due to its advanced remission rate/duration; however, a larger controlled clinical study is required to confirm our findings.

show abstract

Section: A B Csupporting

confidence: 78%

Splenectomy with chemotherapyvssurgery alone as initial treatment for splenic marginal zone lymphoma

Milošević¹

2009

WJG

View full text Add to dashboard Cite

show abstract

“…11 Looking at the IGHV sequences, we previously reported that SMZLs and WM/LPLs show different antigen exposure histories. 12 We and others found that SMZLs are characterized by an overrepresentation of the IGHV1-2 gene, with a low level of IGHV somatic mutation, no antigenic selection pressure and with long CDR3 amino-acid sequences. 13,14 These features suggested a history of chronic antigen stimulation with autoreactivity and without evidence for a germinal center passage.…”

Section: Introductionmentioning

confidence: 80%

“…The WM/LPL IGHV gene repertoire is completely different from that of SMZLs as it is characterized by an overrepresentation of IGHV3-23 genes with high IGHV mutation rates, strong data supporting antigenic selection pressure and short CDR3 segments. 12,16 These features indicate that WM/LPL tumor B cells are of a postgerminal center B-cell origin, having been submitted to T-dependant antigen selection. [17][18][19] Thus, MALT lymphomas, SMZLs and WM/LPLs exhibit significant and markedly different IGHV gene repertoires and characteristics, fully agreeing with the fact that these lymphomas correspond to three different entities.…”

Section: Introductionmentioning

confidence: 99%

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

et al. 2012

Self Cite

View full text Add to dashboard Cite

To clarify the relationships between marginal zone lymphomas (MZLs) and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas (WM/LPLs), immunoglobulin heavy chain variable gene (IGHV) features were analyzed and the occurrence of MYD88 L265P mutations was identified in a series of 123 patients: 53 MZLs from the spleen (SMZLs), 11 from lymph nodes (NMZLs), 28 mucosa-associated lymphatic tissue (MALT) lymphomas and 31 WM/LPLs. SMZLs were characterized by overrepresentation of IGHV1-2 gene rearrangements with a canonical motif, without selection pressure and with long CDR3 segments. NMZLs had increased frequencies of IGHV3 genes. The IGHV gene was unmutated in most cases, often with long CDR3 segments. MALT lymphomas were usually associated with a mutated IGHV gene, but with the absence of selection pressure. WM/LPLs were associated with an IGHV3-23 overrepresentation and high IGHV mutation rate, with features of selection pressure and short CDR3 segments. MYD88 L265P mutations were almost restricted exclusively to WM/LPL patients. Taken all diagnoses together, all patients with MYD88 L265P mutations had an immunoglobulin M peak and almost all patients except one had bone marrow infiltration. These results demonstrate that the history of antigen exposure of the four entities studied was different and MYD88 L265P was specifically associated with WM/LPLs. WM/LPL may thus be functionally associated with constitutive nuclear factor-κB activation.

show abstract

“…Plasmacytic cases presented with IgG or IgM + IgG monoclonal cells and a 6q deletion more frequently than in the entire series (38% versus 14%), although this difference was not statistically significant. There was no association with IGHV3‐23, which has been described as being recurrent in LPL . In fact, there are no unambiguous criteria for this differential diagnosis, and cases with a significant monoclonal plasma cell component, a high degree of bone marrow involvement by a lymphoplasmacytic infiltrate or clinical presentation suggestive of LPL were excluded from this study.…”

Section: Discussionmentioning

confidence: 97%

“…There was no association with IGHV3-23, which has been described as being recurrent in LPL. 34 In fact, there are no unambiguous criteria for this differential diagnosis, and cases with a significant monoclonal plasma cell component, a high degree of bone marrow involvement by a lymphoplasmacytic infiltrate or clinical presentation suggestive of LPL were excluded from this study. Importantly, molecular and cytogenetic findings could help to refine the diagnosis in difficult cases.…”

Section: Discussionmentioning

confidence: 99%

Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases

Traverse-Gléhen

Bachy²,

Baseggio

et al. 2013

Histopathology

View full text Add to dashboard Cite

show abstract

Splenic marginal zone lymphomas and lymphoplasmacytic lymphomas originate from B-cell compartments with two different antigen-exposure histories

Cited by 6 publications

References 13 publications

Splenectomy with chemotherapyvssurgery alone as initial treatment for splenic marginal zone lymphoma

Splenectomy with chemotherapyvssurgery alone as initial treatment for splenic marginal zone lymphoma

IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas

Immunoarchitectural patterns in splenic marginal zone lymphoma: correlations with chromosomal aberrations, IGHV mutations, and survival. A study of 76 cases

Contact Info

Product

Resources

About